全球重組蛋白生產服務市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計重組蛋白生產服務市場將從 2025 年的 66.1 億美元成長到 2034 年的 294.3 億美元，2026 年至 2034 年的複合年成長率為 18.05%。

由於對生物製藥和先進治療性蛋白質的需求不斷成長，全球重組蛋白生產服務市場正在迅速擴張。製藥和生物技術公司正將生產外包給專業的契約製造組織（CMO），以降低營運成本並提高效率。腫瘤學、免疫學和罕見疾病領域的研究進展也推動了對重組蛋白服務的需求。

關鍵成長要素包括臨床試驗數量的增加、生物相似藥的擴張以及哺乳動物和微生物平台等表達系統的進步。對高品質、可擴展生產流程日益成長的需求正在推動對先進生產設施的投資。此外，監管機構對品質合規性的日益重視正在加強生物技術公司與服務供應商之間的合作。

隨著全球生物製劑開發平臺的不斷擴展，未來前景依然強勁。蛋白質工程和純化製程的技術創新將進一步提高產量和成本效益。隨著個人化醫療和標靶治療的日益普及，重組蛋白生產服務預計將持續保持長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球重組蛋白生產服務市場：依服務類型分類

• 市場分析、洞察與預測
• 非臨床和臨床服務
• 商業製作服務

第5章 全球重組蛋白生產服務市場：依宿主細胞類型分類

• 市場分析、洞察與預測
• 哺乳動物細胞
• 細菌細胞
• 昆蟲細胞
• 酵母和真菌
• 其他

第6章 全球重組蛋白生產服務市場：依最終用戶分類

• 市場分析、洞察與預測
• 製藥和生物技術公司
• 學術研究機構

第7章 全球重組蛋白生產服務市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 亞太其他地區
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Lonza Group AG
  • Boehringer Ingelheim International GmbH
  • FUJIFILM Diosynth Biotechnologies
  • Merck KGaA
  • Bruker Corporation（InVivo BioTech Services GmbH）
  • Sino Biological Inc
  • GenScript Biotech Corporation
  • Kaneka Corporation（Kaneka Eurogentec SA）
  • Polyplus Transfection（Xpress Biologics）
  • Boster Biological Technology
  • Trenzyme GmbH

The Recombinant Proteins Manufacturing Services Market size is expected to reach USD 29.43 Billion in 2034 from USD 6.61 Billion (2025) growing at a CAGR of 18.05% during 2026-2034.

The Global Recombinant Proteins Manufacturing Services Market is expanding rapidly due to increasing demand for biologics and advanced therapeutic proteins. Pharmaceutical and biotechnology companies are outsourcing production to specialized contract manufacturing organizations to reduce operational costs and enhance efficiency. Growing research in oncology, immunology, and rare diseases is fueling demand for recombinant protein services.

Key growth drivers include rising clinical trials, expansion of biosimilars, and advancements in expression systems such as mammalian and microbial platforms. The push for high-quality and scalable production processes is encouraging investments in state-of-the-art manufacturing facilities. Additionally, regulatory emphasis on quality compliance is strengthening partnerships between biotech firms and service providers.

Future prospects remain strong as the biologics pipeline continues to expand globally. Technological innovation in protein engineering and purification processes will further improve yield and cost-effectiveness. As personalized medicine and targeted therapies gain traction, recombinant protein manufacturing services are poised for sustained long-term growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Service Type

• Pre-clinical & Clinical Services
• Commercial Production Services

By Host Cell

• Mammalian Cells
• Bacterial Cells
• Insect Cells
• Yeast & Fungi
• Others

By End-User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes

COMPANIES PROFILED

• Lonza Group AG, Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies, Merck KGaA, Bruker Corporation InVivo BioTech Services GmbH, Sino Biological Inc, GenScript Biotech Corporation, Kaneka Corporation Kaneka Eurogentec SA, Polyplus Transfection Xpress Biologics, Boster Biological Technology, Trenzyme GmbH
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Service Type
• 4.2. Pre-clinical & Clinical Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Commercial Production Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET: BY HOST CELL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Host Cell
• 5.2. Mammalian Cells Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Bacterial Cells Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Insect Cells Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Yeast & Fungi Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Service Type
  • 7.2.2 By Host Cell
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Service Type
  • 7.3.2 By Host Cell
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Service Type
  • 7.4.2 By Host Cell
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Service Type
  • 7.5.2 By Host Cell
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Service Type
  • 7.6.2 By Host Cell
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Lonza Group AG
  • 9.2.2 Boehringer Ingelheim International GmbH
  • 9.2.3 FUJIFILM Diosynth Biotechnologies
  • 9.2.4 Merck KGaA
  • 9.2.5 Bruker Corporation (InVivo BioTech Services GmbH)
  • 9.2.6 Sino Biological Inc
  • 9.2.7 GenScript Biotech Corporation
  • 9.2.8 Kaneka Corporation (Kaneka Eurogentec S.A.)
  • 9.2.9 Polyplus Transfection (Xpress Biologics)
  • 9.2.10 Boster Biological Technology
  • 9.2.11 Trenzyme GmbH